Episurf Medical is preparing to launch patient-specific Episealer® implants to treat osteochondral lesions of the talus in the ankle. The company seeks to perform first procedures in 2Q18.
This represents a new direction for the technology which Episurf has developed to treat damaged knee cartilage, with a patient-specific design based on medical imaging and 3D modeling. (Three Episealer knee devices are approved and commercialized in Europe, presently.)
In 2016, a surgeon implanted one patient in Germany with a custom-made Episurf device to treat an ankle joint lesion. The device was built to the surgeon’s specifications in a complex case for which a patient-specific implant was reported to be the only option. The procedure was deemed successful and the patient reported excellent results at 12-month follow-up.
Present approaches to treat osteochondral talus defects include arthroscopic debridement and bone marrow stimulation, autograft transfer, autogenous cancellous bone graft, ACI, metal resurfacing, etc.
Source: Episurf Medical AB